Clinical trials: Oxycontin
Withdrawal Symptoms
A Study to Evaluate Withdrawal Effects Following Dosing of Oxycodone/Naltrexone in Methadone-Maintained Subjects
This single-center study is a randomized, double-blind, active-controlled, multiple-dose, parallel group study to evaluate the potential withdrawal effects, safety and tolerability, and pharmacokinetic and pharmacodynamic effects…
- Trial name
- NCT02391571
- Testing
- Oxycodone/Naltrexone Capsules, Oxycodone
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Elite Laboratories, Inc
Pain
A Study of the Effectiveness and Safety of Sustained-release Hydromorphone (a Strong Opioid) in Patients With Chronic Noncancer Pain.
The purpose of this study is to compare the effectiveness and safety of sustained- release hydromorphone, formulated to release slowly over time, taken once daily, and controlled- release oxycodone taken twice daily, in patients…
- Trial name
- NCT00261495
- Testing
- OROS hydromorphone HCl, Oxycodone
- Where
- 52 sites in Czechia, Denmark and 8 more
- Volunteers
- 504 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Chronic Pain
Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain
Evaluate the efficacy of treatment with the fentanyl buccal tablet (FBT) compared with immediate release oxycodone treatment in alleviating breakthrough pain (BTP) in opioid tolerant patients with chronic pain.
- Trial name
- NCT00813488
- Testing
- Fentanyl Buccal Tablet, Immediate release oxycodone
- Where
- 50 sites in United States
- Volunteers
- 213 people
- Sponsor
- Cephalon
Chronic Low Back Pain
Oxycodone DETERx™ Versus Placebo in Chronic Low Back Pain (CLBP)
The purpose of this study is to evaluate the analgesic efficacy of Oxycodone DETERx compared with placebo in opioid-experienced and opioid-naive subjects with moderate-to-severe chronic low back pain requiring around-the-clock…
- Trial name
- NCT01685684
- Testing
- Oxycodone DETERx
- Where
- 45 sites in United States
- Volunteers
- 740 people
- Sponsor
- Collegium Pharmaceutical, Inc.
Moderate to Severe Pain Due to Diabetic Polyneuropathy
A Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Polyneuropathy
To show superior analgesic efficacy of OXN PR in addition to a patient's current dose of pregabalin compared to pregabalin alone.
- Trial name
- NCT00944697
- Testing
- Oxycodone Naloxone
- Where
- Germany
- Volunteers
- 98 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Pain, Knee Osteoarthritis
A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
The purpose of this study is to evaluate whether tapentadol (CG5503) prolonged-release (PR) tablets at doses of 100-250 mg twice daily provide a better pain relief in patients with moderate to severe chronic pain due to…
- Trial name
- NCT00486811
- Testing
- Tapentadol ER (100 to 250 mg twice daily), Oxycodone CR (20 to 50 mg twice daily)
- Where
- 100 sites in Austria, Croatia and 11 more
- Volunteers
- 990 people
- Sponsor
- Grünenthal GmbH
Pain
Oxycodone-naloxone Prolonged Release Tablets in Relieving Opioid-related Constipation
The primary objective is to demonstrate that patients taking oxycodone/naloxone prolonged release tablets have improvement in symptoms of constipation compared to subjects taking oxycodone prolonged release tablets alone.
- Trial name
- NCT00412100
- Testing
- Oxycodone naloxone prolonged release tablets (OXN)
- Sponsor
- Mundipharma Research GmbH & Co KG
Pain, Cancer
Clinical Study of KW-2246 in Patients With Cancer Pain
This study is a Phase II open-label study to investigate the recommended conversion ratio (oral morphine dose to KW-2246) when switching oral morphine or oxycodone to KW-2246 in cancer patients.
- Trial name
- NCT00355628
- Testing
- KW-2246 (fentanyl citrate)
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Healthy
Fed Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg Tablets
The objective of this open-label, randomized, two-period crossover study was to compare the oral bioavailability of a Mallinckrodt test tablet formulation of oxycodone 30 mg to an equivalent oral dose of a commercially available…
- Trial name
- NCT00853736
- Testing
- Roxicodone™ tablet 30 mg, Oxycodone hydrochloride tablet 30 mg
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Mallinckrodt
Moderate to Severe Idiopathic RLS With Daytime Symptoms
Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Placebo to Demonstrate Improvement in Symptoms of Restless Legs Syndrome (RLS) in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms
The primary objective for the 12-week Titration-/Maintenance Period is: To demonstrate superior efficacy of OXN PR compared to PLA in the improvement of symptom severity of RLS.
- Trial name
- NCT01112644
- Testing
- Oxycodone naloxone prolonged release tablets (OXN PR)
- Where
- 3 sites in Germany, Spain and 1 more
- Volunteers
- 205 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Healthy
A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets Under Fasting Conditions
To compare the relative bioavailability of oxycodone HCl 5 mg / ibuprofen 400 mg tablets (Actavis Elizabeth LLC, Lot No. PI-1565) with that of COMBONOX® tablets (Forest Pharmaceuticals, Inc., Lot No.
- Trial name
- NCT00864526
- Testing
- Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose, COMBONOX® tablets, single dose
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.
Healthy
Pharmacokinetics And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers
To estimate the pharmacokinetics and relative bioavailability of oxycodone after administration of 40 mg doses of PF-00345439 formulations taken whole under fed conditions and after chewing under fasted conditions in healthy…
- Trial name
- NCT01717027
- Testing
- Oxycodone
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Pain Therapeutics
Opioid Abuse Nondependent
Nasal Human Abuse Potential of PTI-821
The study will evaluate the human abuse liability of PTI-821 (oxycodone extended-release capsules) when administered nasally compared to crushed oxycodone IR tablets and crushed OxyContin tablets, also administered nasally.
- Trial name
- NCT03475862
- Testing
- PTI-821 capsule Manipulated, PTI-821 Non-manipulated, OxyContin
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Pain Therapeutics
Pain
Cebranopadol Effects on Ventilatory Drive, Central Nervous System (CNS) and Pain.
Opioids are potent painkillers but come with serious adverse effects ranging from addiction to potentially lethal respiratory depression via activation of μ-opioid receptors (MOP) at specific sites in the central nervous system.
- Trial name
- NCT05491785
- Testing
- Cebranopadol 600 µg, Cebranopadol 800 µg, Cebranopadol 1000 µg
- Where
- 2 sites in Netherlands
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tris Pharma, Inc.
Pain
Oxycodone-naloxone in Relieving Opioid-related Constipation
The primary objective of this study is to demonstrate that subjects with moderate to severe non-malignant pain taking oxycodone/naloxone prolonged release tablets have improvement in symptoms of constipation compared to subjects…
- Trial name
- NCT00412152
- Testing
- Oxycodone nalaxone prolonged release tablets (OXN)
- Sponsor
- Mundipharma Research GmbH & Co KG
Chronic Noncancer Pain
Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain
The study will provide information to assess the benefits versus risks of extended exposure to oxycodone HCl and naltrexone HCl extended-release capsules in a chronic noncancer pain population.
- Trial name
- NCT01428583
- Testing
- oxycodone HCl and naltrexone HCl extended-release capsules
- Where
- 32 sites in United States
- Volunteers
- 395 people
- Sponsor
- Pfizer
Healthy
A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers
To determine whether the bioavailability of the controlled-release test formulation is at least as high as that for the commercial reference drug.
- Trial name
- NCT01677065
- Testing
- Oxycodone controlled-release test formulation, Immediate-release reference drug
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pain, Intractable
Phase II Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Cancer Pain- Assessment of Effectiveness, Safety and Pharmacokinetics -
The purpose of this study is to verify the effectiveness, safety and pharmacokinetics of fentanyl transdermal matrix patches containing either 12.5 mcg/hr, 25 mcg/hr, or 50 mcg/hr in Japanese patients with cancer pain who have…
- Trial name
- NCT00216658
- Testing
- fentanyl
- Volunteers
- 87 people
- Sponsor
- Janssen Pharmaceutical K.K.
Post Operative Pain
OXN PR Compared to OXY PR in Subjects With Postoperative Pain After Knee Arthroplasty
The purpose of this study is to demonstrate that treatment with OXN PR tablets is non inferior to treatment with OXY PR tablets in terms of analgesic efficacy in patients with postoperative pain after knee arthroplasty based on…
- Trial name
- OXN4505 (NCT01083485)
- Testing
- Oxycodone/Naloxone PR 20/10mg or 10/5mg tablets, Oxycodone
- Where
- Finland
- Volunteers
- 137 people
- Sponsor
- Mundipharma Oy
Cancer, Pain
A Study to Compare the Titration Efficacy and Safety of Control-released Oxycodone and Immediate-released Oxycodone in Patients With Moderate to Severe Cancer Pain
This study is to evaluate the efficacy and safety of a titration method by selects 10 mg control-released (CR) oxycodone tablet as background drug in combined with immediate-released (IR) oxycodone, compared to conventional…
- Trial name
- NCT03176199
- Testing
- Oxycodone
- Where
- 4 sites in Taiwan
- Volunteers
- 30 people
- Sponsor
- Taiwan Mundipharma Pharmaceuticals Ltd.